Latest News and Press Releases

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today...

 EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered...

Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided...

Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially...

Planegg/Martinsried, November 26, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided...

Planegg/Martinsried, November 12, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars...